Header Logo

Connection

Heather Feigelson to Aged

Back to Details
This is a "connection" page, showing publications Heather Feigelson has written about Aged.
Heather Feigelson
Connection Strength
1.756
Aged
  1. The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022 Feb 25; 22(1):209.
    View in: PubMed
    Score: 0.093
  2. A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors. BMC Cancer. 2020 May 03; 20(1):373.
    View in: PubMed
    Score: 0.082
  3. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study. Cancer Med. 2019 08; 8(9):4508-4516.
    View in: PubMed
    Score: 0.077
  4. Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey. Support Care Cancer. 2019 Jan; 27(1):147-156.
    View in: PubMed
    Score: 0.072
  5. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br J Cancer. 2018 02 20; 118(4):471-479.
    View in: PubMed
    Score: 0.070
  6. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jun; 11(3):393-400.
    View in: PubMed
    Score: 0.065
  7. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.058
  8. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One. 2014; 9(5):e94977.
    View in: PubMed
    Score: 0.054
  9. Feasibility of self-collection of fecal specimens by randomly sampled women for health-related studies of the gut microbiome. BMC Res Notes. 2014 Apr 01; 7:204.
    View in: PubMed
    Score: 0.054
  10. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 2013 May; 216(5):966-75.
    View in: PubMed
    Score: 0.050
  11. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. BMC Res Notes. 2012 Apr 25; 5:196.
    View in: PubMed
    Score: 0.047
  12. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 2011 Apr; 22(4):573-9.
    View in: PubMed
    Score: 0.043
  13. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010 Oct 01; 19(19):3873-84.
    View in: PubMed
    Score: 0.042
  14. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2553-7.
    View in: PubMed
    Score: 0.039
  15. Successful genome-wide scan in paired blood and buccal samples. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):1023-5.
    View in: PubMed
    Score: 0.033
  16. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006 Jul 01; 107(1):12-21.
    View in: PubMed
    Score: 0.031
  17. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1236-7.
    View in: PubMed
    Score: 0.031
  18. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
    View in: PubMed
    Score: 0.031
  19. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Res Treat. 2024 Dec; 208(3):577-587.
    View in: PubMed
    Score: 0.028
  20. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst. 2024 Aug 01; 116(8):1384-1394.
    View in: PubMed
    Score: 0.028
  21. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1084-5.
    View in: PubMed
    Score: 0.027
  22. Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. Eur J Hum Genet. 2015 Feb; 23(2):260-3.
    View in: PubMed
    Score: 0.027
  23. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004 Feb; 13(2):220-4.
    View in: PubMed
    Score: 0.027
  24. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013 Dec; 15(12):933-40.
    View in: PubMed
    Score: 0.025
  25. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):161-4.
    View in: PubMed
    Score: 0.025
  26. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes Control. 2001 Dec; 12(10):895-902.
    View in: PubMed
    Score: 0.023
  27. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
    View in: PubMed
    Score: 0.022
  28. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000; 2(4):277-82.
    View in: PubMed
    Score: 0.021
  29. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 1999 Aug 15; 59(16):3908-10.
    View in: PubMed
    Score: 0.020
  30. Re: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1997 Dec 03; 89(23):1810-2.
    View in: PubMed
    Score: 0.017
  31. Monitoring Lung Cancer Screening Use and Outcomes at Four Cancer Research Network Sites. Ann Am Thorac Soc. 2017 Dec; 14(12):1827-1835.
    View in: PubMed
    Score: 0.017
  32. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 01; 29(1):143-156.
    View in: PubMed
    Score: 0.017
  33. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
    View in: PubMed
    Score: 0.017
  34. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15; 57(6):1063-5.
    View in: PubMed
    Score: 0.017
  35. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women. Am J Epidemiol. 2017 02 15; 185(4):264-273.
    View in: PubMed
    Score: 0.016
  36. Estrogens and breast cancer. Carcinogenesis. 1996 Nov; 17(11):2279-84.
    View in: PubMed
    Score: 0.016
  37. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
    View in: PubMed
    Score: 0.016
  38. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
    View in: PubMed
    Score: 0.015
  39. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014 Dec; 99(12):4632-40.
    View in: PubMed
    Score: 0.014
  40. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994 Sep 15; 140(6):526-34.
    View in: PubMed
    Score: 0.014
  41. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):91-101.
    View in: PubMed
    Score: 0.012
  42. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
    View in: PubMed
    Score: 0.012
  43. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA. 2012 Jun 13; 307(22):2400-9.
    View in: PubMed
    Score: 0.012
  44. Improving quality of breast cancer surgery through development of a national breast cancer surgical outcomes (BRCASO) research database. BMC Cancer. 2012 Apr 03; 12:136.
    View in: PubMed
    Score: 0.012
  45. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):673-80.
    View in: PubMed
    Score: 0.012
  46. Variability in reexcision following breast conservation surgery. JAMA. 2012 Feb 01; 307(5):467-75.
    View in: PubMed
    Score: 0.012
  47. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43(12):1210-4.
    View in: PubMed
    Score: 0.011
  48. Coronary disease and stroke in patients with large-vessel peripheral arterial disease. Drugs. 1991; 42 Suppl 5:16-21.
    View in: PubMed
    Score: 0.011
  49. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011 Feb; 96(2):E360-7.
    View in: PubMed
    Score: 0.011
  50. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer. 2010 Dec 15; 127(12):2928-35.
    View in: PubMed
    Score: 0.011
  51. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol. 2010 Aug 15; 172(4):419-29.
    View in: PubMed
    Score: 0.010
  52. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
    View in: PubMed
    Score: 0.010
  53. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.010
  54. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
    View in: PubMed
    Score: 0.010
  55. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res. 2010 Mar 15; 70(6):2389-96.
    View in: PubMed
    Score: 0.010
  56. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
    View in: PubMed
    Score: 0.010
  57. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet. 2009 Oct 01; 18(19):3749-57.
    View in: PubMed
    Score: 0.010
  58. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control. 2009 Oct; 20(8):1261-9.
    View in: PubMed
    Score: 0.010
  59. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):297-305.
    View in: PubMed
    Score: 0.009
  60. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008 Oct 15; 123(8):1877-82.
    View in: PubMed
    Score: 0.009
  61. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):73-9.
    View in: PubMed
    Score: 0.009
  62. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
    View in: PubMed
    Score: 0.009
  63. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul; 39(7):870-4.
    View in: PubMed
    Score: 0.008
  64. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
    View in: PubMed
    Score: 0.008
  65. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007; 9(1):R9.
    View in: PubMed
    Score: 0.008
  66. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006; 8(5):R54.
    View in: PubMed
    Score: 0.008
  67. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005 Nov; 1(5):e68.
    View in: PubMed
    Score: 0.008
  68. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005; 7(6):R1168-73.
    View in: PubMed
    Score: 0.008
  69. Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. Am J Epidemiol. 2005 Oct 15; 162(8):734-42.
    View in: PubMed
    Score: 0.007
  70. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):261-4.
    View in: PubMed
    Score: 0.007
  71. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002 Sep; 11(9):795-800.
    View in: PubMed
    Score: 0.006
  72. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 May 01; 94(9):2490-501.
    View in: PubMed
    Score: 0.006
  73. Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes Control. 2002 Apr; 13(3):271-7.
    View in: PubMed
    Score: 0.006
  74. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 Jan 15; 94(2):500-11.
    View in: PubMed
    Score: 0.006
  75. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 2001 Feb 01; 61(3):848-9.
    View in: PubMed
    Score: 0.005
  76. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996 Nov; 172(5):487-9; discussion 489-90.
    View in: PubMed
    Score: 0.004
  77. IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol. 1996 Feb; 49(2):203-9.
    View in: PubMed
    Score: 0.004
  78. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 06; 326(6):381-6.
    View in: PubMed
    Score: 0.003

© 2024 Kaiser Permanente